Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone

References

• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357: 2123–2132.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357: 2133–2142.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Hussein M, Swem AS, et al. Long-term outcomes and safety of continuous lenalidomide plus dexamethasone (Len+ Dex) treatment in patients (Pts) with relapsed or refractory multiple myeloma (RRMM). Blood 2011;118(Suppl. 1): Abstract 2929.
   Google Scholar
• Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010;95:1738–1744.
   PubMed Web of Science ®Google Scholar
• Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009;146:164–170.
   PubMed Web of Science ®Google Scholar
• Lonial S, Baz R, Swern AS, et al. Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone. Blood 2009;114 (Suppl. 1): Abstract 2879.
   Google Scholar
• National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) [Internet]. 2006. Available from: http://ctep.info.nih.gov/protocolDevelopment/electronic_applications/docs/ct
   Google Scholar
• Durie BG, Harousseau JL, Mignel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147–2152.
   PubMed Web of Science ®Google Scholar
• Reece DE, Masih-Khan E, Goswami RS, et al. Incidence and characteristics of secondary myelodysplastic syndrome developing during lenalidomide-based regimens in relapsed and/or refractory multiple myeloma patients. Blood 2010;116(Suppl. 1): Abstract 1877.
   Google Scholar
• Mateos MV, García-Sanz R, Colado E, et al. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Br J Haematol 2008;140:324–326.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Hussein M, Swern AS, et al. Full dose of lenalidomide for 12 months followed by a lower maintenance dose improves progression-free survival in patients with relapsed/refractory multiple myeloma. Blood 2009;112(Suppl. 1): Abstract 2874.
   Google Scholar
• Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009;114:772–778.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Soulier J, Fermand JP, et al. IFM and MAG groups. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010;24:623–628.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Dimopoulos MA, Weber DM, et al. Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): analysis from MM-009 and MM-010 randomized phase III clinical trials [abstract]. Blood 2006;108(Suppl. 1): Abstract 3554.
   Google Scholar
• Baz R, Lonial S, Hussein M, et al. Lenalidomide (LEN) therapy in combination with dexamethasone (DEX) is associated with a low incidence of viral infections. Blood 2010;116(Suppl. 1): Abstract 1950.
   Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol 2010;11:29–37.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Romiplostim in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy (NCT01676961). New York University School of Medicine. October 2013. Available from: <http://clinicaltrials.gov>
   Google Scholar
• Wang ES, Lyons RM, Larson RA, et al. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol 2012;5:71.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Filgrastim in treating patients with bortezomib-, carfilzomib-, or IMID-refractory multiple myeloma (NCT01537861). Washington University School of Medicine. August 2013. Available from: <http://clinicaltrials.gov>
   Google Scholar
• Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 2010;115:605–614.
   PubMed Web of Science ®Google Scholar
• Reece D, Kouroukis T, Leblanc R, et al. Practical approaches to the use of lenalidomide in multiple myeloma: a Canadian consensus. Adv Hematol 2012;2012:621958.
   PubMedGoogle Scholar